Study of Exercise and Heart Function in Patients With Heart Failure and Pulmonary Vascular Disease (EXEC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01418248|
Recruitment Status : Completed
First Posted : August 17, 2011
Last Update Posted : January 9, 2014
|Condition or disease|
|Exercise Tolerance Dyspnea Heart Failure Pulmonary Hypertension|
- The broad objective of this proposal is to characterize the dynamic changes in cardiopulmonary mechanics during stress in patients with exertional dyspnea, establishing a comprehensive multimodality diagnostic approach to the evaluation of exercise intolerance.
- The specific objective is to prospectively compare established and novel parameters derived from echocardiography and CPX with simultaneous, gold standard invasive measures of cardiovascular hemodynamics at rest and with exercise stress to define the role of noninvasive testing in the diagnostic workup.
- The primary hypothesis is that combined ExE and CPX can noninvasively identify HFpEF.
|Study Type :||Observational|
|Actual Enrollment :||108 participants|
|Official Title:||Evaluation of Exercise Intolerance and Right Heart Function in Patients With Heart Failure and Pulmonary Vascular Disease|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||August 2013|
- Diagnostic Utility ExE and CPX [ Time Frame: Same day as clinically indicated Right Heart Catheterization (RHCath) ]
- Multiple integrated measures of cardiovascular function derived from RHCath, ExE and CPX along with rest/exercise natriuretic peptide levels [ Time Frame: Same day as clinically indicated RHCath ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01418248
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Barry Borlaug, MD||Mayo Clinic|